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Lack of an effect of protease inhibitor use on glucose
tolerance during pregnancy
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Objective: WehypothesizedthatHIV-positivewomenonproteaseinhibitors(PIs)wouldbemorelikelytohavean
elevated glucola test result than those not on PIs.
Methods: We reviewed our database of all HIV-positive pregnant women seen at our hospital. Serum glucose
was measured 1 hour following a 50-g glucola load, at approximately 26–28 weeks of gestation. Statistical
analysis was performed using Student’s t-test, Fisher’s exact test, and the Mann–Whitney rank sum test.
Results: Forty-one HIV-infected pregnant women with glucola testing were seen between January 1, 1997 and
March 1, 2000. Fourteen patients were on PIs at the time of glucola. One patient in each group had an abnormal
glucola test result (glucose ‡ 140 mg/dl); both had normal 3-hour glucose tolerance tests. The glucola test results
were similar between the PI-exposed and unexposed, with a mean difference of 5.8 mg/dl (95% confidence
interval 9.2–20.8 mg/dl). Two neonates (both exposed to PI) had hypoglycemia (glucose < 40 mg/dl).
Conclusions: The use of PIs does not significantly increase the risk of an elevated glucola result, nor is the
mean glucola result increased in the women on PIs. The finding of hypoglycemia in neonates exposed to PIs
merits further investigation.
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INTRODUCTION
Beginning in January 1998, the Public Health
Service Task Force recommended that pregnant
women infected with HIV who had been receiv-
ing antiretroviral therapy prior to pregnancy
should continue treatment during pregnancy1.
Additionally, pregnant women infected with HIV
who have had no prior antiretroviral therapy
should be counseled on the use of combination
therapy during pregnancy. Combination therapy,
which often consists of two nucleoside analogue
reverse transcriptase inhibitors and a protease
inhibitor (PI), is currently the typical treatment of
choice for HIV-infected adults who are not
pregnant2,3. Treatment recommendations con-
tinue to evolve, however, with many experts also
recommending ‘protease-sparing’ regimens2,3.
Although phase I trials of several PIs in preg-
nant HIV-infected women are ongoing, there is
currently very little data regarding the safety and
tolerance of PIs in pregnant women or neonates.
Hyperglycemia and overt diabetes are well-
documented side-effects that have occurred with
several antiretroviral medications, particularly the
PIs. Themechanism of PI-induced hyperglycemia
is thought to be an increase in peripheral
insulin-resistance4,5. The onset of hyperglycemia
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Clinical study 187following PI exposure is variable with reported
ranges to be from 1 month to over 1 year. Preg-
nancy is a state of increased insulin resistance, and
glucose intolerance – or gestational diabetes –
complicates approximately 2% of pregnancies6.
In the United States, the diagnosis of gestational
diabetes is usually made by first performing a
1-hour post-glucola load as a screening test in the
late second or early third trimester of pregnancy.
Whenabnormalresultsareobtainedforthe1-hour
test, a 3-hour glucola test is performed. It was our
hypothesis that the use of PIs in pregnancy may
exacerbate this insulin resistance, resulting in an
increased risk of hyperglycemia and gestational
diabetes.
SUBJECTS AND METHODS
A prospectively maintained database was retro-
spectively reviewed for all HIV-infected pregnant
women cared for at the Medical College of
Virginia hospitals between January 1997, when PI
use began, and March 2000. All patients were
routinely offered antepartum, intrapartum, and
neonatal zidovudine therapy based on the results
of the ACTG 076 trial7. Beginning in 1998,
zidovudine monotherapy was discouraged and
those women not desiring or not candidates for
combination therapy with PI were offered dual
therapy with zidovudine and lamivudine. Patients
receiving antiretroviral therapy prior to pregnancy
were counseled to continue this same therapy
during pregnancy with the addition of zido-
vudine if they were not already taking it. Selected
patients not receiving antiretroviral therapy prior
to pregnancy were offered combination therapy,
usually consisting of two nucleoside reverse
transcriptase inhibitors and a PI. These patients
generally had HIV RNA plasma viral loads greater
than 5–10 000 or CD4 counts lower than 500, as
per the contemporary recommendations of the
US Department of Health and Human Services
Panel on Clinical Practice for the Treatment of
HIV Infection1. Those patients who were non-
compliant with past therapy or who were
non-compliant with obstetric care were generally
not offered PI-containing combination therapy.
At approximately 26–28 weeks’ gestation,
serum glucose levels were measured 1 hour
following an oral load of 50 g glucose in the form
of glucola. If the serum glucose was ‡ 140 mg/dl,
the patient subsequently underwent a 3-hour
glucose tolerance test. A fasting glucose level
was obtained and then serum glucose levels were
measured 1, 2 and 3 hours following a 100-g
glucose load. Normal values were defined as
< 105, 190, 165, and 145 mg/dl respectively. If
two or more values were abnormal, the patient
was classified as a gestational diabetic6. HIV
RNA plasma viral loads and CD4 counts were
obtained at the first prenatal visit and at approxi-
mately 3-month intervals until delivery. In most
cases, increases in the plasma viral load prompted
re-evaluation and modification of the patient’s
antiretroviral regimen.
Neonatal glucose levels were measured only if
the baby showed clinical signs of hypoglycemia, as
determined by medical or nursing nursery staff.
Hypoglycemia was defined by a glucose value of
< 40 mg/dl. Neonatal HIV infection was evalu-
ated by performing quantitative PCR for HIV
RNAonneonatalbloodatbirth,2 weeks,6 weeks
and 6 months, and HIV antibody testing at
15 months of age. Neonatal HIV infection was
diagnosed if any HIV RNA was detected, or if
levels of anti-HIV IgG antibody remained detect-
able at 15 months of age.
Statistical analysis was performed using SPSS,
version 10.0 (SPSS, Chicago, IL). A Fisher’s exact
test was performed on discrete variables, and
either a Student’s t-test (for normally distributed
variables) or a Mann–Whitney rank sum test (for
those not normally distributed) was performed
on continuous variables. A p-value of < 0.05 was
considered significant.
RESULTS
At the Medical College of Virginia, we cared for
45 HIV-infected pregnant women with continu-
ing pregnancies between January 1, 1997 and
March 1, 2000. Twenty-three of the 45 patients
were prescribed combination therapy including a
PI prior to their delivery. Nine ofthese 23 patients
conceived while taking combination therapy and
continued therapy for the duration of the preg-
nancy. The median gestational age at which com-
bination therapy was initiated in the remaining
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Eight patients on combination therapy started in
the third trimester after glucola screening had
been completed. Twenty-two of the 45 patients
were not prescribed combination therapy (five
declined, ten were known to be non-compliant
with previously prescribed medications, four had
low viral load counts, two had minimal prenatal
care, and one had failed PI therapy in the past).
Generally, these patients were prescribed zido-
vudine with lamivudine added in some cases, as
described earlier. One patient declined all anti-
retroviral therapy during her pregnancy, but
accepted intrapartum zidovudine and nevirapine.
Table 1 describes the demographic characteris-
tics of both groups. There were no significant
differences in race or gestational age between the
two groupsat the time ofglucola screening. Those
patients who were prescribed PI-containing com-
binationtherapytendedtohavelowerCD4counts
and lower viral loads, although these trends were
not statistically significant. Four patients (one on
combinationtherapy)did nothave glucola screen-
ing performed prior to delivery due to scant pre-
natalcare. In theremaining 41patients, there were
nosignificantdifferencesinthemean glucolaresult
or in the incidence of abnormal glucola results
between women taking a PI and those who were
not. The mean difference in glucola test results
was 5.8 mg/dl (95% confidence interval (CI)
9.2–20.8 mg/dl). No patient in either group was
diagnosed with gestational diabetes. The median
duration of PI use prior to glucola screening was
27 weeks (range 2–31 weeks.) Twelve patients
(86%) had been on PI for at least 2 months, and
eight (57%) had been on PI for at least 6 months.
There were no significant differences in glucola
results when the analysis was confined to those
patients with PI exposures of 2 or 6 months prior
to testing.
Of the 14 patients on PI-containing regimens,
the majority (nine) were taking nelfinivir plus
lamivudine and zidovudine. Other combinations
includedindinivir pluslamivudine and zidovudine
(two patients), nelfinivir plus zidovudine and
nevirapine (one), nelfinivir plus lamivudine and
stavudine (one), and saquinivir plus lamivudine
and stavudine (one patient).
As shown in Table 2, there were no significant
differences between the PI-exposed and un-
exposed patients in gestational age or birth weight
at the time of delivery, and only one infant
exposed to PI was born prematurely, at 36 weeks.
Two infants exposed to Nelfinivir were diagnosed
with symptomatic hypoglycemia (serum glucose
levels of 26 and 35 mg/dl, respectively) in the
nursery. Only two unexposed infants exhibited
symptoms of hypoglycemia and were tested;
neither was found to be hypoglycemic. No other
metabolic abnormalities were seen in the PI-
exposed neonates nor were any congenital
anomalies or dysmorphology noted. The two
babies with hypoglycemia were treated symptom-
atically and did well. These differences remained
non-significant when patients exposed to PI
only in the third trimester (seven patients) were
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PI (n = 14) No PI (n = 27) p-value
Mean age, years ± SD
Ethnic origin, n (%)
African-American
Caucasian
AIDS, number affected (%)
Mean CD4 count, cells/mm3 ± SD
Median viral load, copies/ml (range)
Mean gesatational age, weeks ± SD
Mean glucola result, mg/dl ± SD
Abnormal glucola (‡ 140 mg/dl), n (%)
30.1 ± 6.4
12 (86)
2 (14)
4 (29)
401 ± 170
1022 (0–70 300)
27.2 ± 1.4
108 ± 25
1 (7)
26.3 ± 4.7
21 (78)
6 (22)
5 (19)
465 ± 293
2790 (0–88 000)
27.7 ± 3
102 ± 21
1 (4)
0.04
NS
NS
NS
NS
NS
NS
NS
NS
SD, standard deviation; NS, not significant
Table 1 Characteristics of HIV-infected pregnant women at the time of glucola testing, comparing those taking
protease inhibitors (PI) and those who were not (No PI)included in the PI-exposed group (data not
shown).
DISCUSSION
In our patient population, the use of PIs in
pregnancy does not significantly increase the risk
of having an elevated glucola value nor does it
increase the risk of gestational diabetes. The small
sample size and relatively short duration of PI
exposure are limitations that may increase the
chance of a beta error. Given that the 95% CI
for the difference between the two groups is
-9.2–20.8, our results show that if there is an
increase in glucose intolerance, the magnitude of
the effect is likely not clinically significant. In
addition, hyperglycemia and dyslipidemias have
been reported following only 1 month of PI
exposure.Ithasbeenpostulatedthattheperipheral
insulin resistance seen in these patients may be
a result of PI binding to cytoplasmic retinoic-
acid-binding protein type 1 and low-density
lipoprotein-receptor-related protein, and the
resultant hyperlipidemia8. Hadigan and colleagues
reported that HIV-infected women, even in the
absence of antiretroviral therapy, had hyper-
insulinemia and hypertriglyceridemia comparedto
HIV-negative women9. Although we did not
detect an increased incidence of glucose intoler-
ance in our HIV-infected pregnant population,
baseline hyperinsulinemia and insulin resistance as
a result of the pregnancy could potentially mask
any further increases in insulin resistance due to PI
use. A potentialconfounderisthefactthatmanyof
the patients who were prescribed PIs had more
advanced HIV disease than the women in the
comparison group.
We did not measure lipid levels or insulin
resistancedirectlyashasbeendoneinotherstudies,
but searched for sequelae of increased insulin
resistance, namely hyperglycemia and glucose
intolerance. Perhaps a better indicator of maternal
insulin resistance and possibly subtle hyper-
glycemia is the occurrence of neonatal hypo-
glycemia in two of the PI-exposed neonates.
Fetal beta-cell hyperplasia following exposure to
maternalhyperglycemia,leadingtoan exaggerated
insulin release and resulting in postnatal hypo-
glycemia, as seen followingdelivery in neonates of
diabetic mothers, is a possible explanation. How-
ever, a direct effect of placentally transferred PI
cannot be excluded. As practitioners gain experi-
ence and increasingly prescribe the use of novel
antiretroviral therapies during pregnancy, sur-
veillance for subtle and delayed effects, such as
neonatal hypoglycemia, should be continued.
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